Literature DB >> 12746108

More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde.

M Rahnasto1, H Raunio, A Poso, R O Juvonen.   

Abstract

1. A rapid 96-well plate assay method was developed and validated to measure liver microsomal coumarin 7-hydroxylation in vitro. 2. The method was used to test inhibition of human and mouse CYP2A enzymes by three phenylethylamine derivatives 2-(p-tolyl)-ethylamine, amphetamine, 2-phenylethylamine and benzaldehyde, and two of its derivatives, 4-methylbenzaldehyde and 4-methoxybenzaldehyde. 3. The benzaldehyde derivatives were more potent inhibitors of CYP2A5 than the phenylethylamines. The K(ic) value of 4-methylbenzaldehyde was 3.4 micro M and for 4-methoxybenzaldehyde it was 0.86 micro M for CYP2A5. 4. Amphetamine is a weak inhibitor of CYP2A6, whereas benzaldehyde is a suicide inhibitor with K(inact) = 0.16 min(-1) and K(I) = 18 micro M. The K(ic) values of 2-phenylethylamine, 2-(p-tolyl)-ethylamine, 4-methylbenzaldehyde and 4-methoxybenzaldehyde were 1.13, 0.23, 0.36 and 0.73 micro M for CYP2A6, respectively. 5. Novel potent inhibitors were found for CYP2A6 and, except for 4-methoxybenzaldehyde, all the compounds inhibited CYP2A5 and CYP2A6 enzymes differentially. These data add to the refinement of CYP2A enzyme active sites and provide chemical leads for developing novel chemical inhibitors of the CYP2A6 enzyme.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746108     DOI: 10.1080/0049825031000085979

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  6 in total

1.  Impact of E-Cigarette Liquid Flavoring Agents on Activity of Microsomal Recombinant CYP2A6, the Primary Nicotine-Metabolizing Enzyme.

Authors:  Brett R Winters; Tavleen K Kochar; Phillip W Clapp; Ilona Jaspers; Michael C Madden
Journal:  Chem Res Toxicol       Date:  2020-06-18       Impact factor: 3.739

2.  Celery extract inhibits mouse CYP2A5 and human CYP2A6 activities via different mechanisms.

Authors:  Xiao Deng; Qianghong Pu; Erhao Wang; Chao Yu
Journal:  Oncol Lett       Date:  2016-10-25       Impact factor: 2.967

3.  Development of a new predictive model for interactions with human cytochrome P450 2A6 using pharmacophore ensemble/support vector machine (PhE/SVM) approach.

Authors:  Max K Leong; Yen-Ming Chen; Hong-Bin Chen; Po-Hong Chen
Journal:  Pharm Res       Date:  2008-12-23       Impact factor: 4.200

4.  Benzylmorpholine analogs as selective inhibitors of lung cytochrome P450 2A13 for the chemoprevention of lung cancer in tobacco users.

Authors:  Linda C Blake; Anuradha Roy; David Neul; Frank J Schoenen; Jeffrey Aubé; Emily E Scott
Journal:  Pharm Res       Date:  2013-06-12       Impact factor: 4.200

Review 5.  Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy.

Authors:  James C Ermer; Michael Pennick; Glen Frick
Journal:  Clin Drug Investig       Date:  2016-05       Impact factor: 2.859

Review 6.  An Inventory of Methods for the Assessment of Additive Increased Addictiveness of Tobacco Products.

Authors:  Suzanne van de Nobelen; Anne S Kienhuis; Reinskje Talhout
Journal:  Nicotine Tob Res       Date:  2016-01-26       Impact factor: 4.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.